Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Assets: 2021-2024

Historic Assets for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $193.6 million.

  • Amylyx Pharmaceuticals' Assets rose 44.68% to $362.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $362.7 million, marking a year-over-year increase of 44.68%. This contributed to the annual value of $193.6 million for FY2024, which is 62.58% down from last year.
  • According to the latest figures from FY2024, Amylyx Pharmaceuticals' Assets is $193.6 million, which was down 62.58% from $517.5 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Assets registered a high of $517.5 million during FY2023, and its lowest value of $105.6 million during FY2021.
  • Moreover, its 3-year median value for Assets was $391.5 million (2022), whereas its average is $367.5 million.
  • Its Assets has fluctuated over the past 5 years, first skyrocketed by 270.64% in 2022, then slumped by 62.58% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Assets (Yearly) stood at $105.6 million in 2021, then spiked by 270.64% to $391.5 million in 2022, then soared by 32.19% to $517.5 million in 2023, then crashed by 62.58% to $193.6 million in 2024.